1. Home
  2. TNGX vs RFI Comparison

TNGX vs RFI Comparison

Compare TNGX & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • RFI
  • Stock Information
  • Founded
  • TNGX 2014
  • RFI 1992
  • Country
  • TNGX United States
  • RFI United States
  • Employees
  • TNGX N/A
  • RFI N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • RFI Investment Managers
  • Sector
  • TNGX Health Care
  • RFI Finance
  • Exchange
  • TNGX Nasdaq
  • RFI Nasdaq
  • Market Cap
  • TNGX 317.4M
  • RFI 321.0M
  • IPO Year
  • TNGX N/A
  • RFI N/A
  • Fundamental
  • Price
  • TNGX $1.77
  • RFI $11.92
  • Analyst Decision
  • TNGX Strong Buy
  • RFI
  • Analyst Count
  • TNGX 7
  • RFI 0
  • Target Price
  • TNGX $12.33
  • RFI N/A
  • AVG Volume (30 Days)
  • TNGX 782.3K
  • RFI 69.8K
  • Earning Date
  • TNGX 05-07-2025
  • RFI 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • RFI 8.25%
  • EPS Growth
  • TNGX N/A
  • RFI N/A
  • EPS
  • TNGX N/A
  • RFI N/A
  • Revenue
  • TNGX $42,069,000.00
  • RFI N/A
  • Revenue This Year
  • TNGX N/A
  • RFI N/A
  • Revenue Next Year
  • TNGX N/A
  • RFI N/A
  • P/E Ratio
  • TNGX N/A
  • RFI N/A
  • Revenue Growth
  • TNGX 15.17
  • RFI N/A
  • 52 Week Low
  • TNGX $1.72
  • RFI $9.62
  • 52 Week High
  • TNGX $12.02
  • RFI $12.52
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 32.71
  • RFI 45.42
  • Support Level
  • TNGX $1.80
  • RFI $11.61
  • Resistance Level
  • TNGX $2.04
  • RFI $12.52
  • Average True Range (ATR)
  • TNGX 0.21
  • RFI 0.19
  • MACD
  • TNGX 0.01
  • RFI -0.04
  • Stochastic Oscillator
  • TNGX 7.46
  • RFI 34.07

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

Share on Social Networks: